CBIO
NASDAQCrescent Biopharma Inc.
Price$11.79-0.49 (-3.99%)
01:30 PM07:45 PM
News · 26 weeks68-40%
2026-04-192026-10-11
Mix2690d
- Other10(38%)
- Insider8(31%)
- SEC Filings6(23%)
- Offering1(4%)
- Analyst1(4%)
Latest news
25 items- SECSEC Form 8-K filed by Crescent Biopharma Inc.8-K - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)
- PRCrescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001More than 125 patients dosed in ASCEND across the United States, Europe and South Korea; dose escalation complete On track to report initial monotherapy data from ASCEND in Q1 2027, including antitumor response for a first-line non-small cell lung cancer (NSCLC) cohort Enrolling patients in CR-001 plus standard of care chemotherapy combinations from ASCEND expansion cohorts in several solid tumor types in treatment-naive and previously treated patients, including first-line NSCLC, colorectal, biliary tract, gastric and endometrial cancers; on track to report initial data from hundreds of patients in mid-2027 Potential to start the first of multiple CR-001 Phase 3 studies in early 2028 Cr
- PRCrescent Biopharma Announces Grants of Inducement AwardsWALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 81,525 shares of the Company’s ordinary shares to six non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the "Inducement Plan"). The options were approved on October 5, 2026 and were material to each employee's acceptan
- ANALYSTCrescent Biopharma upgraded by H.C. Wainwright with a new price targetH.C. Wainwright upgraded Crescent Biopharma from Neutral to Buy and set a new price target of $36.00
- PRCrescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid TumorsPhase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to initiate in the fourth quarter of 2026 Initial clinical data expected in the second half of 2027 WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CR-002, a topoisomerase inhibitor
- PRCrescent Biopharma Announces Grants of Inducement AwardsWALTHAM, Mass., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 31,200 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the "Inducement Plan"). The options were approved on September 24, 2026 and were material to each employee's acce
- INSIDERChief Scientific Officer Pinkas Jan sold $11,778 worth of Ordinary Shares (658 units at $17.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 21,581 units (SEC Form 4) (withholding obligation)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- INSIDERChief Medical Officer Im Ellie Eunkyung sold $11,152 worth of Ordinary Shares (623 units at $17.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 21,446 units (SEC Form 4) (withholding obligation)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- INSIDEROfficer Lynch Ryan sold $4,296 worth of Ordinary Shares (240 units at $17.90) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 13,631 units (SEC Form 4) to cover taxes4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- INSIDERChief Financial Officer Scalzo Richard William sold $10,167 worth of Ordinary Shares (568 units at $17.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 19,730 units (SEC Form 4) (for withholding tax)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- INSIDERPresident and COO Mcneill Jonathan sold $77,235 worth of Ordinary Shares (4,570 units at $16.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 134,588 units (SEC Form 4) to cover taxes4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- INSIDEROfficer Bispham Barbara Harlin sold $11,098 worth of Ordinary Shares (620 units at $17.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 18,710 units (SEC Form 4) (for withholding tax)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- INSIDERChief Executive Officer Brumm Joshua T sold $159,775 worth of Ordinary Shares (9,447 units at $16.91) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 271,765 units (SEC Form 4) to cover taxes4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- SECSEC Form S-8 filed by Crescent Biopharma Inc.S-8 - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)
- PRCrescent Biopharma Announces Grants of Inducement AwardsWALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 58,650 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the "Inducement Plan"). The options were approved on September 8, 2026 and were material to each employee's accep
- PRCrescent Biopharma to Present at September Investor ConferencesWALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in September: 2026 Cantor Global Healthcare Conference, fireside chat on Thursday, September 10, 2026 at 1:35 p.m. ET in New York.Morgan Stanley 24th Annual Global Healthcare Conference, fireside chat on Monday, September 14, 2026 at 5:35 p.m. ET in New York. A live webcast of each presentation will be available in the Investors section of the Company's website
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Crescent Biopharma Inc.SCHEDULE 13G/A - CRESCENT BIOPHARMA, INC. (0001253689) (Subject)
- PRCrescent Biopharma Announces Grants of Inducement AwardsWALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 19,425 shares of the Company’s ordinary shares to one non-executive employee as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the "Inducement Plan"). The options were approved on July 31, 2026 and were material to the employee's acceptance o
- SECSEC Form EFFECT filed by Crescent Biopharma Inc.EFFECT - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)
- SECSEC Form POS AM filed by Crescent Biopharma Inc.POS AM - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)
- SECSEC Form 424B3 filed by Crescent Biopharma Inc.424B3 - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)
- SECSEC Form 10-Q filed by Crescent Biopharma Inc.10-Q - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)
- SECCrescent Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)
- PRCrescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business HighlightsEnrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients CR-001 + sacituzumab tirumotecan (sac-TMT) Phase 2 trial in NSCLC, first ADC combination study in Kelun-Biotech collaboration, underway in China Phase 1/2 trial of CR-003, an ITGB6-targeted ADC, ongoing in China; Phase 1/2 global trial of CR-002, a PD-L1-targeted ADC, on track to initiate in second half of 2026 Multiple key clinical data readouts across the portfolio anticipated beginning in Q1 2027 Completed $143.7 million public offering extending expected cash runway into the second half of
- PRCrescent Biopharma Announces Grants of Inducement AwardsWALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 52,500 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the "Inducement Plan"). The options were approved on July 22, 2026 and were material to each employee's acceptance
CBIO FAQ
7 questionsWhat does Crescent Biopharma Inc. do?
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company engineer proteases to develop improved or novel molecules to treat diseases that result from dysregulation of the complement and coagulation cascades. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously administered engineered coagulation; and Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare...Where does CBIO stock trade?
Crescent Biopharma Inc. (CBIO) is listed on NASDAQ.What sector and industry is CBIO in?
Crescent Biopharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Crescent Biopharma Inc. go public?
Crescent Biopharma Inc. (CBIO) completed its IPO in 2014.What are analysts saying about CBIO?
Crescent Biopharma Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $3600.00 price target on 2026-10-06. Recent price targets range from $2500.00 to $3600.00.What companies are similar to CBIO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CBIO side-by-side with any of them on Quantisnow.How can I track CBIO on Quantisnow?
Quantisnow aggregates Crescent Biopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CBIO to receive live email and push alerts on every new disclosure.